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NEW IN 2017: UPDATE OF POLISH FORUM  
FOR PREVENTION GUIDELINES ON  
PROPHYLACTIC PHARMACOTHERAPY
1. Acetylsalicylic acid (ASA) not recommended in primary 
prevention of cardiovascular diseases (CVD)
2. New antiplatelet drugs after acute coronary syndrome 
(ACS) and percutaneous coronary interventions (PCI)
3. Sacubitril-valsartan for selected patients with heart failure 
(HF) with reduced ejection fraction (EF)
4. Recommendations on stroke prevention therapy in atrial 
fibrillation (AF) patients
5. Modified recommendations on combination therapy 
with oral anticoagulant and antiplatelets in AF patients
1. PROPHYLACTIC PHARMACOTHERAPY
Prophylactic pharmacotherapy is, second only to lifestyle 
changes, the primary method of prevention of CVD. The re-
duction, by half, of the mortality from coronary heart disease 
in Poland between 1991 and 2005 resulted from a reduction 
of the prevalence of CVD risk factors (54%) and implemented 
therapies (37%), mainly pharmacological [1].
2. AIMS OF PROPHYLACTIC PHARMACOTHERAPY
Prophylactic pharmacotherapy includes the use of drugs, 
which, in primary and/or secondary prevention, decrease 
the risk of developing CVD and death from CVD. It in-
cludes drugs:
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 — that improve survival (reduce the risk of death from any 
cause): antiplatelet drugs, statins (discussed in the PFP 
guidelines on dyslipidaemia [2]), beta-blockers, angiotensin-
-converting enzyme inhibitors (ACEI), angiotensin receptor 
blockers (ARB), aldosterone antagonists (MRA), omega-3 
fatty acids, combination of valsartan and sacubitril;
 — that reduce the risk of CVD events with no effect on 
overall survival: influenza vaccination, ivabradine [3];
 — that improve the quality of life with no effect on the 
risk of CVD events: nitrates, digoxin [4].
3. ACETYLSALICYLIC ACID (ASA)
Indications:
 — primary prevention of CVD — ASA reduces the risk 
of myocardial infarction (MI) in men by 32% and the 
risk of stroke in women by 17%; however, it does not 
affect the risk of death. Its chronic use increases the risk 
of bleeding (including life-threatening gastrointestinal or 
intracranial bleeding). Therefore, routine use of ASA is 
not recommended in primary prevention;
 — secondary prevention of CVD — in patients with 
known CVD and in patients with AF, the use of ASA 
reduces the risk of death by 15%. ASA is recommend-
ed in secondary prevention of CVD, unless there are 
contraindications.
Doses:
 — in a single loading dose of 150–325 mg in ACS or during 
PCI in patients not previously treated with ASA, and the 
loading dose of 160–325 mg in ischaemic stroke (in the 
case of thrombolytic treatment of stroke, ASA should 
not be administered on the first day);
 — indefinitely at a dose of 75–100 mg once a day in pa-
tients with diagnosed CVD, and 50–325 mg once a day 
in patients after ischaemic stroke; in cases of hypersen-
sitivity to ASA, clopidogrel is recommended at a dose of 
75 mg once a day. 
Main contraindications to use of ASA: hypersensitivity 
or intolerance to the drug and active bleeding [5–9].
4. DUAL ANTIPLATELET THERAPY (DAPT)
The most common combinations of antiplatelet drugs are: 
clopidogrel, ticagrelor or prasugrel in addition to ASA.
In acute MI, the addition of clopidogrel to ASA dur-
ing hospitalisation reduces the risk of death by 7%. Adding 
clopidogrel to ASA for 3–12 months after ACS without ST 
segment elevation reduces the risk of CVD events in 12-month 
follow-up by 14%. The use of ticagrelor or prasugrel instead 
of clopidogrel in addition to ASA in patients with MI treated 
with primary PCI results in an additional reduction in risk of 
CVD deaths and events.
Recommended dose of antiplatelet drugs (P2Y12 in-
hibitors):
 — clopidogrel — loading dose of 600 mg, maintenance 
dose of 75 mg once a day; 
 — prasugrel — loading dose 60 mg, maintenance dose of 
10 mg once a day;
 — ticagrelor — loading dose 180 mg, maintenance dose of 
90 mg twice daily.
Indications: Use of DAPT is recommended in patients:
 — with ACS — in a single loading dose followed by 
a maintenance dose for 12 months (preferred use of ASA 
plus ticagrelor or prasugrel; when they are not available 
or contraindicated — ASA plus clopidogrel);
 — with stable coronary artery disease (CAD), treated 
with PCI with stent implantation — in a single load-
ing dose followed by maintenance dose — for a month 
after bare metal stent implantation and for six months 
after drug-eluting stent implantation (routine use of 
clopidogrel is recommended, in case of stent thrombo-
sis on clopidogrel therapy — ticagrelor or prasugrel is 
recommended) in addition to ASA; 
 — with ischaemic stroke — in an acute period only mono-
therapy with ASA is used; in secondary prevention mono-
therapy with ASA or clopidogrel is recommended. DAPT 
increases the risk of intracranial bleeding; therefore, at pres-
ent DAPT with clopidogrel and ASA is not recommended.
Main contraindications to use of P2Y12 inhibitors: 
hypersensitivity, severe liver damage, active bleeding, and 
additionally: for clopidogrel — recent stroke; for prasugrel 
— previous stoke or transient ischaemic attack; and for tica-
grelor — previous intracranial haemorrhage and the parallel 
use of CYP3A4 inhibitors [6–9].
5. BETA-BLOCKERS
Beta-blockers, when used chronically after MI, reduce the risk 
of death by 23%. Bisoprolol, carvedilol and metoprolol (suc-
cinate) reduce the risk of death in patients with symptomatic 
HF with reduced EF (HFrEF) by 30%. Nebivolol reduces the 
risk of death or hospitalisation in patients with HF > 70 years 
of age by 14%. Beta-blockers used in combination with 
ACEIs reduce the risk of death in asymptomatic patients with 
reduced left ventricular ejection fraction (LVEF) by 25–30%. 
Indications: It is recommended that beta-blockers be 
used indefinitely to prevent CVD events in patients:
 — after MI; oral therapy is preferred and should be 
initiated after stabilisation of the haemodynamic status;
 — with HFrEF in functional class II–IV (bisoprolol, 
carvedilol, metoprolol [succinate], nebivolol) in combi-
nation with ACEIs or ARBs.
Beta-blockers are also used as antiarrhythmic, antihyper-
tensive, and antianginal drugs.
Main contraindications to use of beta-blockers: hyper-
sensitivity to the drug, poorly controlled asthma, atrioventricu-
lar block of second or third degree, sick sinus syndrome, sinus 
bradycardia < 50/min, cardiogenic shock, decompensated HF 
(Killip class ≥ III), vasospastic angina, and severe peripheral ar-
terial disease. In the case of contraindications to beta-blockers 
in patients after MI without evidence of HF, verapamil should 
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be considered as an alternative (it reduces the risk of death 
by 36%) [4, 6, 7, 9, 10].
6. ANGIOTENSIN-CONVERTING  
ENZYME INHIBITORS (ACEIs)
ACEIs reduce the risk of death in patients with CAD without 
HF by 13%, in patients with HF of different aetiologies by 
16–27%, and in patients with asymptomatic left ventricular 
dysfunction of different aetiologies by 14–19%.
Indications: ACEIs are recommended to reduce the risk 
of cardiovascular events in patients:
 — with HFrEF in functional class II–IV;
 — with CAD and coexisting conditions such as HF, diabe-
tes, or hypertension;
 — with diabetes and albuminuria or hypertension;
 — in the treatment of hypertension.
Their use should be considered also in patients with 
diagnosed stable CAD and after MI. ACEIs are not homo-
geneous drugs. When choosing a specific medication, one 
should consider the results of clinical studies and the lack 
of a class effect, especially in the prevention of vascular 
complications. 
Main contraindications to use of ACEIs: hypersensitiv-
ity to the drug, a history of angioedema, bilateral renal artery 
stenosis or stenosis of a single renal artery, pregnancy and lac-
tation, cardiomyopathy with left ventricular outflow tract ob-
struction, severe aortic stenosis, serum potassium > 5 mmoL/L 
(relative), serum creatinine > 220 µmoL/L (2.5 mg/dL) (rela-
tive) [4, 6, 7, 9, 10].
7. ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)
In patients with HFrEF, who cannot tolerate ACEIs, the use of 
ARBs compared to a placebo reduces the risk of death from 
CVD by 20% and hospitalisation for HF by 39%. In patients 
after MI with HFrEF, ARBs affect the risk of death similarly to 
ACEIs. A combination of valsartan and sacubitril (angiotensin 
receptor neprilysin inhibitor [ARNI]) reduce the risk of death 
by 16% and hospitalisation for HF by 21% in patients with 
HFrEF in comparison to enalapril. 
Indications: ARBs are recommended to improve 
prognosis in patients with hypertension, HFrEF, or after MI, 
who do not tolerate ACEI. All three drugs that inhibit the 
renin–angiotensin–aldosterone system (ACEI, ARB, and al-
dosterone antagonist) should not be given together. ARNI is 
recommended as a replacement for an ACEI in patients with 
HFrEF, who remain symptomatic despite optimal treatment 
with an ACEI, a beta-blocker, and MRA.
Main contraindications to use of ARBs: are the same 
as for ACEI, except for angioedema. An ARB should not be 
added in patients receiving an ACEI and an aldosterone an-
tagonist. Combined treatment with an ACEI or ARB and ARNI 
is contraindicated [4, 9, 10].
8. ALDOSTERONE ANTAGONISTS (MRAs)
MRAs reduce the risk of death in patients with LVEF ≤ 35% 
and functional class III or IV treated with an ACEI and a loop 
diuretic by 30% (spironolactone), and in patients after MI 
with LVEF ≤ 40% and symptoms of HF or diabetes treated 
with ACEI or ARB, beta-blocker, and diuretics by 15% 
(eplerenone).
Indications: MRAs are recommended to improve prog-
nosis in patients with HF with LVEF ≤ 35% and functional 
class II–IV, who are optimally treated with beta-blockers and 
ACEIs or ARBs.
Main contraindications to use of MRAs: hypersensitiv-
ity to the drug, blood potassium > 5.0 mmoL/L, severe renal 
impartment — creatinine clearance < 30 mL/min, severe 
liver dysfunction — Child and Pugh class C, and the use 
of a combination of ACEI and ARB or the combination of 
potassium-sparing diuretic with potassium supplements [10].
9. ORAL ANTICOAGULATION — STROKE  
PREVENTION THERAPY IN AF PATIENTS
Oral anticoagulation (OAC) reduces the risk of stroke in AF 
by 65%, while antiplatelet drugs only by 20%.
Indications: OAC is recommended in AF patients with 
a CHA2DS2-VASc score of 2 or more for men, and 3 or more 
for women. OAC should also be considered for men with 
a CHA2DS2-VASc score of 1 and women with a score of 2 
(Table 1):
 — non-vitamin K antagonist oral anticoagulants (NOACs), 
i.e. direct thrombin inhibitor (dabigatran) or factor Xa 
inhibitors (rivaroxaban, apixaban or edoxaban), dose 
dependent on renal function and the risk of bleeding;
 — vitamin K antagonists, i.e. warfarin, acenocumarol in 
adjusted dose (INR 2.0–3.0).
NOACs are not recommended in patients with mechani-
cal heart valves or moderate-to-severe mitral stenosis.
Table 1. CHA2DS2-VASc score for stroke risk assessment in 
atrial fibrillation patients [11]
CHA2DS2-VASc risk factor Points
Congestive heart failure 1
Hypertension 1
Age 75 years or older 2
Diabetes mellitus 1
Previous stroke, transient ischaemic attack,  
or thromboembolism
2
Vascular disease (previous myocardial infarction,  
peripheral artery disease)
1
Age 65–74 years 1
Sex category (female) 1
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Antiplatelet therapy is not recommended for stroke pre-
vention in AF patients.
Contraindications: hypersensitivity to the drug, preg-
nancy, active bleeding, recent intracranial haemorrhage or 
surgery of the central nervous system or the eye, conditions 
increasing the risk of major bleeding, and for NOAC addition-
ally severe renal impairment.
Combination therapy with OACs and antiplatelets (ASA 
and clopidogrel) in AF patients after ACS or PCI (in particular 
its duration) is dependent on the type of intervention (ACS or 
elective PCI) and assessment the risk of bleeding (i.e. HASBLED 
score) compared to the risk of ACS or stent thrombosis [11].
10. PHARMACOTHERAPY OF RISK FACTORS
Prophylactic pharmacotherapy plays an important role in modi-
fying risk factors for CVD such as dyslipidaemia, hypertension, 
and diabetes, as well as tobacco dependece [2, 12–14].
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